Like Countable?

Install the App

senate Bill S. 1220

Patient Access to Critical Lab Tests Act

bill Progress

  • Not enacted
    The President has not signed this bill
  • The house has not voted
  • The senate has not voted
      senate Committees
      Committee on Finance
    IntroducedJune 9th, 2009

Bill Details

Official information provided by the Congressional Research Service. Learn more or make a suggestion.
The Congressional Research Service writes summaries for most legislation. These summaries are listed here. Countable will update some legislation with a revised summary, title or other key elements.

Suggest an update to this bill using our form.


Patient Access to Critical Lab Tests Act

Official Title

A bill to require that certain complex diagnostic laboratory tests performed by an independent laboratory after a hospital outpatient encounter or inpatient stay during which the specimen involved was collected shall be treated as services for which payment may be made directly to the laboratory under part B of title XVIII of the Social Security Act.


Patient Access to Critical Lab Tests Act - Expresses the sense of Congress that: (1) where practical, Medicare regulations and policies should be written to promote development of and access to certain highly specialized laboratory tests; and (2) certain Medicare regulations should be revised to permit laboratories furnishing such tests to bill for and be paid directly by Medicare for furnishing them. Declares that, whenever a laboratory performs a covered complex diagnostic laboratory test, with respect to a specimen collected from an individual during a period in which the individual is a hospital patient, if the test is performed after such period, the Secretary of Health and Human Services shall treat such test, for purposes of making direct payment to the laboratory, as if the specimen had been collected by the laboratory directly. Defines "covered complex diagnostic laboratory test" as: (1) an analysis of DNA, RNA, chromosomes, proteins, or metabolites that detects, identifies, or quantitates genotypes, mutations, chromosomal changes, biochemical changes, cell response, or protein expression, or gene expression or similar method or is a cancer chemotherapy sensitivity assay or similar method, with certain exceptions; (2) a diagnostic X-ray or other diagnostic test; (3) one developed and performed by a laboratory independent of the hospital in which the specimen involved was collected, and not under any arrangements with such hospital; and (4) one not furnished by such hospital, directly or under any arrangements made by it.

    There are currently no opinions on this bill, be the first to add one!